ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.

A. Mihali,1 E. Sula Karreci,1 A. Kurdi,3 L. Riella,1 Y. Kawano,3 H. Fan,2 P. Singh,2 I. Ghobrial,3 C. Nathan,2 G. Lin,2 J. Azzi.1

1Transplantation Research Center, Harvard Medical School, Boston
2Department of Microbiology and Immunology, Weill Cornell Medicine, NY
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.

Meeting: 2016 American Transplant Congress

Abstract number: 469

Keywords: Antibodies, B cells, Immunosuppression

Session Information

Session Name: Concurrent Session: B cells and Antibody-Mediated Rejection: Animal Models

Session Type: Concurrent Session

Date: Tuesday, June 14, 2016

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:42pm-4:54pm

Location: Room 309

Antibody mediated rejection (AMR) is one of the most important barriers to improving long-term transplant outcomes. Traditional therapies for AMR do not deplete the source of antibody production such as the mature plasma cells. Bortezomib is the only plasma cell-targeted therapy used in humans with AMR. Bortezomib inhibits the constitutive proteasomes (c-20S), cellular proteases that degrade polyubiquitinated proteins and regulate many cell functions. However, c-20S are ubiquitously expressed in tissues and its inhibition leads to apoptotic cell death, which increases the toxicity of inhibition, limiting the use of bortezomib. However, immunoproteasomes (IP or i-20S) are primarily expressed in immune cells. c-20S and i-20S differ only in 3 proteolytic β subunits. We show here that memory B cells and plasma cells increase their expression of i-20S in the spleen and bone marrow in mice with a heart allograft. We hypothesized that i-20S inhibition would target B cell activation, memory B cells and plasma cells without the toxicity of inhibiting c-20S.

We designed and synthesized a novel, specific, non-covalent, small molecule inhibitor (DPLG3) of the IP β5i subunit. DPLG3 inhibited mouse i-20S with IC50 of 9.4 nM and 1500-fold selectivity over mouse c-20S, and inhibited human i-20S with an IC50 of 4.5 nM and 7000-fold selectivity over human c-20S.

C57BL/6 recipients of BALB/c hearts treated with low dose sCTLA4Ig (250 [micro]g on day 2) and 2 weeks injections of DPLG3 (25 mg/kg/day) exhibited indefinite heart survival prolongation compared to control (CTLA4Ig + vehicle) (MST >100 and 30 days respectively, n=6/group, p<0.05).

We found a significant reduction in activated B cells, memory B cells and plasma cells in the spleen and the bone marrow of DPLG3-treated mice compared to vehicle (p<0.05, n=6-8 mice/group). DPLG3 treatment induced significant suppression of donor specific antibodies measured in the serum of allograft recipients (p<0.05, n=6-8 mice/group).

In summary, we designed a novel and safe plasma cell targeted inhibitor that could improve the treatment of AMR in transplant recipients.

CITATION INFORMATION: Mihali A, Sula Karreci E, Kurdi A, Riella L, Kawano Y, Fan H, Singh P, Ghobrial I, Nathan C, Lin G, Azzi J. Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Mihali A, Karreci ESula, Kurdi A, Riella L, Kawano Y, Fan H, Singh P, Ghobrial I, Nathan C, Lin G, Azzi J. Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/designing-and-synthesizing-a-novel-highly-selective-immunoproteasome-inhibitor-that-promotes-long-term-heart-allograft-acceptance-while-reducing-plasma-cells-and-donor-specific-antibodies/. Accessed July 3, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences